TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effectiveness of Differing Levels of Support for Family Mealtimes on Obesity Prevention Among Head Start Preschoolers
Brief Summary: Socioeconomic disparities in early childhood place low-income children at 1.5 to 2 times higher risk for obesity compared to middle- to upper-income children. Obesity interventions have turned toward the promotion of family mealtimes. This study will test the effects of 6 intervention components reflecting differing levels of supports to ultimately reduce childhood obesity prevalence and increase the frequency of healthy family mealtimes and improve dietary quality. The investigators will test 6 intervention components in Phase 1 (Screening Phase), resulting in the implementation and evaluation via a randomized controlled trial of a "final" intervention model in Phase 2 (Confirming Phase). The investigators hypothesize that providing low-income families with effective supports to enhance family capability to plan and implement family mealtimes will lead to improvements in children's adiposity indices, dietary quality and frequency of family meals.


Options:
A: Arm Label: HOP'N After-School Program; Type: EXPERIMENTAL; Interventions: Behavioral: HOP'N After-school Program | Intervention Type: BEHAVIORAL; Name: HOP'N After-school Program; Assigned to Arm(s): HOP'N After-School Program
B: Arm Label: Experimental: Phase 1 Usual Exposure; Type: EXPERIMENTAL; Interventions: Behavioral: Usual Exposure | Arm Label: Experimental: Phase 1 Mealtime support activities; Type: EXPERIMENTAL; Interventions: Behavioral: Mealtime Supports | Arm Label: Experimental: Phase 2- Usual Exposure; Type: EXPERIMENTAL; Interventions: Behavioral: Usual Exposure | Arm Label: Experimental: Phase 2- Meal Delivery and Receipt of Cookware; Type: EXPERIMENTAL; Interventions: Behavioral: Mealtime Supports | Intervention Type: BEHAVIORAL; Name: Mealtime Supports; Assigned to Arm(s): Experimental: Phase 1 Mealtime support activities, Experimental: Phase 2- Meal Delivery and Receipt of Cookware | Intervention Type: BEHAVIORAL; Name: Usual Exposure; Assigned to Arm(s): Experimental: Phase 1 Usual Exposure, Experimental: Phase 2- Usual Exposure
C: Arm Label: BALANCE; Type: EXPERIMENTAL; Interventions: Behavioral: BALANCE | Intervention Type: BEHAVIORAL; Name: BALANCE; Assigned to Arm(s): BALANCE
D: Arm Label: COPE/Healthy Lifestyles TEEN Program; Type: EXPERIMENTAL; Interventions: Behavioral: COPE/Healthy Lifestyles TEEN Program. | Arm Label: Healthy Teens Attention Control Program; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Healthy Teens Attention Control Program | Intervention Type: BEHAVIORAL; Name: COPE/Healthy Lifestyles TEEN Program.; Assigned to Arm(s): COPE/Healthy Lifestyles TEEN Program | Intervention Type: BEHAVIORAL; Name: Healthy Teens Attention Control Program; Assigned to Arm(s): Healthy Teens Attention Control Program

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Long-Term Treatment of Drug Addiction and Unemployment
Brief Summary: The purpose of this clinical trial is to evaluate the effectiveness and economic benefits of a Wage Supplement Model of arranging long-term exposure to employment-based abstinence reinforcement.


Options:
A: Intervention Type: BEHAVIORAL; Name: contingency management and behavioral day treatment; Assigned to Arm(s): N/A
B: Arm Label: IPS Only; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Individual Placement and Support (IPS) supported employment | Arm Label: IPS Plus Wage Supplement; Type: EXPERIMENTAL; Interventions: Behavioral: Abstinence-contingent wage supplements, Behavioral: Individual Placement and Support (IPS) supported employment | Intervention Type: BEHAVIORAL; Name: Abstinence-contingent wage supplements; Assigned to Arm(s): IPS Plus Wage Supplement | Intervention Type: BEHAVIORAL; Name: Individual Placement and Support (IPS) supported employment; Assigned to Arm(s): IPS Only, IPS Plus Wage Supplement
C: Arm Label: ARTEMIS+CM; Type: EXPERIMENTAL; Interventions: Behavioral: Affect Regulation Treatment to Enhance Meth Intervention Success (ARTEMIS), Behavioral: Contingency Management (CM) | Arm Label: Attention-Control+CM; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Contingency Management (CM) | Intervention Type: BEHAVIORAL; Name: Affect Regulation Treatment to Enhance Meth Intervention Success (ARTEMIS); Assigned to Arm(s): ARTEMIS+CM | Intervention Type: BEHAVIORAL; Name: Contingency Management (CM); Assigned to Arm(s): ARTEMIS+CM, Attention-Control+CM
D: Arm Label: Treatment as usual; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Treatment as usual + CBT4CBT; Type: EXPERIMENTAL; Interventions: Behavioral: CBT4CBT | Intervention Type: BEHAVIORAL; Name: CBT4CBT; Assigned to Arm(s): Treatment as usual + CBT4CBT

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Optimizing Rehabilitation for Phantom Limb Pain Using Mirror Therapy and Transcranial Direct Current Stimulation (tDCS)
Brief Summary: This is a two-site study that explores the effects of mirror therapy and transcranial Direct Current Stimulation (tDCS, Soterix ©) in a randomized factorial controlled trial in which patients will be assigned to one of four groups: active tDCS and active MT; sham tDCS and active MT; active tDCS and sham MT (which consists of using a covered mirror for the therapy); and both sham tDCS and sham MT (covered mirror).


Options:
A: Arm Label: Real tDCS; Type: EXPERIMENTAL; Interventions: Device: tDCS | Arm Label: Sham tDCS; Type: PLACEBO_COMPARATOR; Interventions: Device: Sham tDCS | Intervention Type: DEVICE; Name: tDCS; Assigned to Arm(s): Real tDCS | Intervention Type: DEVICE; Name: Sham tDCS; Assigned to Arm(s): Sham tDCS
B: Arm Label: Active tDCS and Active Mirror Therapy; Type: EXPERIMENTAL; Interventions: Device: transcranial Direct Current Stimulation (tDCS): active (Soterix ©), Behavioral: Mirror Therapy: active | Arm Label: Active tDCS and sham Mirror Therapy; Type: EXPERIMENTAL; Interventions: Device: transcranial Direct Current Stimulation (tDCS): active (Soterix ©), Behavioral: Mirror Therapy: Sham | Arm Label: Sham tDCS and active Mirror Therapy; Type: EXPERIMENTAL; Interventions: Behavioral: Mirror Therapy: active, Device: transcranial Direct Current Stimulation (tDCS): sham (Soterix ©) | Arm Label: Sham tDCS and sham Mirrory Therapy; Type: SHAM_COMPARATOR; Interventions: Device: transcranial Direct Current Stimulation (tDCS): sham (Soterix ©), Behavioral: Mirror Therapy: Sham | Intervention Type: DEVICE; Name: transcranial Direct Current Stimulation (tDCS): active (Soterix ©); Assigned to Arm(s): Active tDCS and Active Mirror Therapy, Active tDCS and sham Mirror Therapy | Intervention Type: BEHAVIORAL; Name: Mirror Therapy: active; Assigned to Arm(s): Active tDCS and Active Mirror Therapy, Sham tDCS and active Mirror Therapy | Intervention Type: DEVICE; Name: transcranial Direct Current Stimulation (tDCS): sham (Soterix ©); Assigned to Arm(s): Sham tDCS and active Mirror Therapy, Sham tDCS and sham Mirrory Therapy | Intervention Type: BEHAVIORAL; Name: Mirror Therapy: Sham; Assigned to Arm(s): Active tDCS and sham Mirror Therapy, Sham tDCS and sham Mirrory Therapy
C: Arm Label: 1; Type: PLACEBO_COMPARATOR; Interventions: Other: Transcranial stimulation | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Other: Transcranial stimulation | Intervention Type: OTHER; Name: Transcranial stimulation; Assigned to Arm(s): 1 | Intervention Type: OTHER; Name: Transcranial stimulation; Assigned to Arm(s): 2
D: Arm Label: Group I; Type: ACTIVE_COMPARATOR; Interventions: Device: Real tDCS | Arm Label: Group II; Type: SHAM_COMPARATOR; Interventions: Device: Sham tDCS | Intervention Type: DEVICE; Name: Real tDCS; Assigned to Arm(s): Group I | Intervention Type: DEVICE; Name: Sham tDCS; Assigned to Arm(s): Group II

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effects of a School-based Physical Activity Intervention on Math Achievement - A Randomized Controlled Trial
Brief Summary: Background

Increased physical activity can improve cognition and academic skills. However due to economic concerns and increasing focus on standardized testing, PA in schools often receives little attention and physical education is reduced in many countries in favor of spending more time devoted to academic classes. This tendency is not compatible with the increasing evidence for the association between physical activity, fitness, cognitive and academic performance.

Despite increasing evidence for the association between PA, fitness, cognitive and academic performance, very few longitudinal high-quality studies exists examining the effect of physical activity on academic performance (ref.). Furthermore, to the best of our knowledge only two studies have assessed academic outcomes following the integration of physical activity into the classroom with intervention participants scoring significantly higher in test sections compared to controls which makes generalizing from these results challenging.

To promote policy changes that require more physical activity in school, empirical data are needed to study the effects of school-based physical activity programs. Therefore the investigators carried out a cluster randomized controlled trial conducted to examine the effect on math achievement and executive functions of classroom based PA in math.


Options:
A: Arm Label: Physical activity; Type: EXPERIMENTAL; Interventions: Behavioral: Physical activity | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Physical activity; Assigned to Arm(s): Physical activity
B: Arm Label: Normal math; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Active math; Type: EXPERIMENTAL; Interventions: Behavioral: Physically active math lessons | Intervention Type: BEHAVIORAL; Name: Physically active math lessons; Assigned to Arm(s): Active math
C: Arm Label: Control group; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Cycling to school; Type: EXPERIMENTAL; Interventions: Behavioral: Cycling to school | Intervention Type: BEHAVIORAL; Name: Cycling to school; Assigned to Arm(s): Cycling to school
D: Arm Label: A Healthy School Start Plus intervention; Type: EXPERIMENTAL; Interventions: Behavioral: A Healthy School Start Plus intervention | Arm Label: Control; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: A Healthy School Start Plus intervention | Intervention Type: BEHAVIORAL; Name: A Healthy School Start Plus intervention; Assigned to Arm(s): A Healthy School Start Plus intervention, Control

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Cognitive Intervention After a Brain Tumor
Brief Summary: This study evaluates the feasibility and utility of two behavioural programs designed to reduce cognitive impairments secondary to brain tumors and/or their treatment. One-third of participants will complete training in either program, with the remaining third a wait-list control group.


Options:
A: Arm Label: Brain Training; Type: EXPERIMENTAL; Interventions: Behavioral: Brain Training Program | Arm Label: Brain Health; Type: EXPERIMENTAL; Interventions: Behavioral: Brain Health Program | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Brain Training Program; Assigned to Arm(s): Brain Training | Intervention Type: BEHAVIORAL; Name: Brain Health Program; Assigned to Arm(s): Brain Health
B: Arm Label: WBRT with Hippocampal Avoidance; Type: OTHER; Interventions: Radiation: intensity-modulated radiation therapy | Intervention Type: RADIATION; Name: intensity-modulated radiation therapy; Assigned to Arm(s): WBRT with Hippocampal Avoidance
C: Arm Label: Arm I; Type: EXPERIMENTAL; Interventions: Drug: armodafinil 150 mg | Arm Label: Arm II; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Arm Label: Arm III; Type: EXPERIMENTAL; Interventions: Drug: armodafinil 250 mg | Intervention Type: DRUG; Name: armodafinil 150 mg; Assigned to Arm(s): Arm I | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Arm II | Intervention Type: DRUG; Name: armodafinil 250 mg; Assigned to Arm(s): Arm III
D: Arm Label: Delayed exercise control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Exercise; Type: EXPERIMENTAL; Interventions: Behavioral: Exercise | Intervention Type: BEHAVIORAL; Name: Exercise; Assigned to Arm(s): Exercise

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Telemedicine in Qualifying Care Transition Between Tertiary and Primary Health Care Among Stable Coronary Artery Disease Patients: a Randomized Non-inferiority Trial
Brief Summary: The purpose of this study is to determine whether the telemedicine use in primary health care is effective in the accompaniment of stable coronary artery disease patients who were discharged from the tertiary health care clinics.


Options:
A: Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Procedure: Store and forward teledermatology | Arm Label: Arm 2; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: PROCEDURE; Name: Store and forward teledermatology; Assigned to Arm(s): Arm 1
B: Arm Label: Tertiary care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Primary care; Type: EXPERIMENTAL; Interventions: Other: Telemedicine | Intervention Type: OTHER; Name: Telemedicine; Assigned to Arm(s): Primary care
C: Arm Label: Pre-Implementation Cohort; Type: N/A; Interventions: Other: Usual Care | Arm Label: Post-Implementation Cohort; Type: N/A; Interventions: Other: Blended Telemedicine-Based Integrated Care | Intervention Type: OTHER; Name: Usual Care; Assigned to Arm(s): Pre-Implementation Cohort | Intervention Type: OTHER; Name: Blended Telemedicine-Based Integrated Care; Assigned to Arm(s): Post-Implementation Cohort
D: Arm Label: Teledermatology; Type: EXPERIMENTAL; Interventions: Other: Teledermatology | Arm Label: Usual care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Teledermatology; Assigned to Arm(s): Teledermatology

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Management in Real-life of Patients Hospitalized With Community-acquired Pneumonia in China
Brief Summary: The purpose of this study is to evaluate the disease burden of hospitalized patients with CAP and healthcare-associated pneumonia (HCAP) in real life of China .


Options:
A: Arm Label: Experimental group; Type: EXPERIMENTAL; Interventions: Other: Experimental group | Arm Label: Control group; Type: ACTIVE_COMPARATOR; Interventions: Other: Control group | Intervention Type: OTHER; Name: Experimental group; Assigned to Arm(s): Experimental group | Intervention Type: OTHER; Name: Control group; Assigned to Arm(s): Control group
B: Arm Label: Osteopathic Manipulative Treatment; Type: EXPERIMENTAL; Interventions: Procedure: Osteopathic Manipulative Treatment | Arm Label: Light-touch Treatment; Type: SHAM_COMPARATOR; Interventions: Procedure: Light-touch Treatment | Arm Label: Conventional Care Only; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: PROCEDURE; Name: Osteopathic Manipulative Treatment; Assigned to Arm(s): Osteopathic Manipulative Treatment | Intervention Type: PROCEDURE; Name: Light-touch Treatment; Assigned to Arm(s): Light-touch Treatment
C: Arm Label: Physiotherapy+conventional treatment; Type: EXPERIMENTAL; Interventions: Other: Physiotherapy+conventional treatment | Arm Label: Conventional treatment; Type: ACTIVE_COMPARATOR; Interventions: Drug: Conventional treatment | Intervention Type: OTHER; Name: Physiotherapy+conventional treatment; Assigned to Arm(s): Physiotherapy+conventional treatment | Intervention Type: DRUG; Name: Conventional treatment; Assigned to Arm(s): Conventional treatment
D: Intervention Type: OTHER; Name: other; Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multi-centre, Randomised, Placebo Controlled, Double Blinded, Multiple Dose Trial Investigating Safety, Pharmacokinetics and Pharmacodynamics of Concizumab Administered Subcutaneously to Haemophilia A Subjects (Explorer™3)
Brief Summary: This trial is conducted globally. The aim of this trial is to investigate safety, pharmacokinetics (the exposure of the trial drug in the body) and pharmacodynamics (the effect of the investigated drug on the body) of concizumab administered subcutaneously to haemophilia A subjects.


Options:
A: Arm Label: Pharmacokinetic (PK) evaluation of BAX 855; Type: EXPERIMENTAL; Interventions: Biological: PEGylated Recombinant Factor VIII | Arm Label: FVIII trough target 1-3%; Type: EXPERIMENTAL; Interventions: Biological: PEGylated Recombinant Factor VIII | Arm Label: FVIII trough target 8-12%; Type: EXPERIMENTAL; Interventions: Biological: PEGylated Recombinant Factor VIII | Intervention Type: BIOLOGICAL; Name: PEGylated Recombinant Factor VIII; Assigned to Arm(s): Pharmacokinetic (PK) evaluation of BAX 855 | Intervention Type: BIOLOGICAL; Name: PEGylated Recombinant Factor VIII; Assigned to Arm(s): FVIII trough target 1-3% | Intervention Type: BIOLOGICAL; Name: PEGylated Recombinant Factor VIII; Assigned to Arm(s): FVIII trough target 8-12%
B: Arm Label: Concizumab; Type: EXPERIMENTAL; Interventions: Drug: Concizumab, Drug: placebo | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: Concizumab; Assigned to Arm(s): Concizumab | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Concizumab, Placebo
C: Arm Label: Prophylaxis, high dose (trial duration 52 weeks); Type: EXPERIMENTAL; Interventions: Drug: nonacog beta pegol | Arm Label: Prophylaxis, low dose (trial duration 52 weeks); Type: EXPERIMENTAL; Interventions: Drug: nonacog beta pegol | Arm Label: On-demand (trial duration 28 weeks); Type: EXPERIMENTAL; Interventions: Drug: nonacog beta pegol | Intervention Type: DRUG; Name: nonacog beta pegol; Assigned to Arm(s): Prophylaxis, high dose (trial duration 52 weeks) | Intervention Type: DRUG; Name: nonacog beta pegol; Assigned to Arm(s): Prophylaxis, low dose (trial duration 52 weeks) | Intervention Type: DRUG; Name: nonacog beta pegol; Assigned to Arm(s): On-demand (trial duration 28 weeks)
D: Arm Label: On-demand first; Type: OTHER; Interventions: Drug: activated prothrombin complex concentrate (FEIBA) | Arm Label: Prophylaxis first; Type: OTHER; Interventions: Drug: activated prothrombin complex concentrate (FEIBA) | Intervention Type: DRUG; Name: activated prothrombin complex concentrate (FEIBA); Assigned to Arm(s): On-demand first, Prophylaxis first

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Double-blind Placebo-Controlled Randomized Clinical Trial of Mineralocorticoid Receptor Blockade With Eplerenone After Renal Transplantation : Effect on Graft Function at 3 Months.
Brief Summary: Assess the impact of eplerenone (initiated within 2 hours prior to patient departure to the operating room and administered for 4 days during the post-operative period) on graft function evaluated by the measurement of glomerular filtration rate at 3 months - variable strongly associated with long-term graft survival.


Options:
A: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: spironolactone | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: spironolactone; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2
B: Arm Label: Placebo Oral Tablet; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo Oral Tablet | Arm Label: Spironolactone 25 MG Tablet; Type: ACTIVE_COMPARATOR; Interventions: Drug: Spironolactone 25Mg Tablet | Intervention Type: DRUG; Name: Spironolactone 25Mg Tablet; Assigned to Arm(s): Spironolactone 25 MG Tablet | Intervention Type: DRUG; Name: Placebo Oral Tablet; Assigned to Arm(s): Placebo Oral Tablet
C: Arm Label: Spironolactone 12.5 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Spironolactone | Arm Label: Spironolactone 25 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Spironolactone | Arm Label: Spironolactone 50 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Spironolactone | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Spironolactone | Intervention Type: DRUG; Name: Spironolactone; Assigned to Arm(s): Placebo, Spironolactone 12.5 mg, Spironolactone 25 mg, Spironolactone 50 mg
D: Arm Label: Eplerenone group; Type: EXPERIMENTAL; Interventions: Drug: Eplerenone | Arm Label: Placebo group; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Eplerenone; Assigned to Arm(s): Eplerenone group | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo group

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Maximizing Adherence and Retention for Women and Infants in the Context of Option B+
Brief Summary: This is a 2x2 factorial cluster randomized trial of two interventions to improve retention and adherence for women and infants on Option B+. The overall goal is to determine which intervention (or combination of interventions) maximizes antiretroviral therapy (ART) adherence and retention in care in the context of Option B+ and thus improves maternal and infant health outcomes.The proposed study will be conducted in rural Nyanza Province, Kenya at 20 low-resource primary health care facilities and associated communities supported by Family AIDS Care and Education Services (FACES), a President's Emergency Plan for AIDS Relief (PEPFAR)-funded HIV prevention care, and treatment program, ((AIDS) acquired immune deficiency syndrome, (HIV) human immunodeficiency virus) . The investigators will assess both process and outcome indicators using a 2x2 factorial design, in which equal numbers of clusters will be randomized to one of the interventions (community-based mentor mothers or theory-based mobile text messages), both interventions, or standard of care. The interventions will be added to fully integrated high quality HIV and antenatal, maternal, neonatal, and child health (ANC/MNCH) services already offered at these sites.


Options:
A: Intervention Type: BEHAVIORAL; Name: Pulse; Assigned to Arm(s): N/A
B: Arm Label: Nutrition messages; Type: EXPERIMENTAL; Interventions: Behavioral: SMS | Arm Label: General health messages; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: SMS | Intervention Type: BEHAVIORAL; Name: SMS; Assigned to Arm(s): General health messages, Nutrition messages
C: Arm Label: Controls; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Reminders alone; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Reminders alone | Arm Label: Reminders + compliance-linked incentives; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Reminders alone, Behavioral: Compliance-linked incentives | Intervention Type: BEHAVIORAL; Name: Reminders alone; Assigned to Arm(s): Reminders + compliance-linked incentives, Reminders alone | Intervention Type: BEHAVIORAL; Name: Compliance-linked incentives; Assigned to Arm(s): Reminders + compliance-linked incentives
D: Arm Label: cMM and Text Messaging; Type: OTHER; Interventions: Behavioral: cMM, Behavioral: Text Messaging | Arm Label: cMM Only; Type: OTHER; Interventions: Behavioral: cMM | Arm Label: Text Messaging Only; Type: OTHER; Interventions: Behavioral: Text Messaging | Arm Label: Neither cMM nor Text Messaging; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: cMM; Assigned to Arm(s): cMM Only, cMM and Text Messaging | Intervention Type: BEHAVIORAL; Name: Text Messaging; Assigned to Arm(s): Text Messaging Only, cMM and Text Messaging

Answer: D